VALBIOTIS
22.2.2021 17:42:09 CET | Business Wire | Press release
Regulatory News:
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient's First Visit in the Phase II HEART clinical study evaluating TOTUM-070, an innovative active substance for the reduction of blood LDL-cholesterol levels, a risk factor for cardiovascular disease.
The Company is stepping up development of TOTUM-070 in 2021, with the completion of a complementary clinical study and preclinical work on lipid metabolism. These preclinical results will be submitted to the American Heart Association (AHA) meeting at the end of the year.
Murielle CAZAUBIEL, member of the Management Board and Director of Development and Medical Affairs at VALBIOTIS, comments: “The start of recruitment for the Phase II HEART clinical study kicks off a decisive year for the development of TOTUM-070. This study should demonstrate the clinical efficacy of our active substance against excess blood LDL-cholesterol, a major risk factor for cardiovascular disease worldwide. Pending these results in early 2022, and given the potential of TOTUM-070, we have decided to conduct several complementary clinical and preclinical studies simultaneously this year. This is an ambitious program, which should provide a maximum amount of data by early next year and confirm TOTUM-070 as an additional innovation for people at risk of cardiovascular disease.”
The randomized, double-blind, placebo-controlled, multicenter, Phase II HEART clinical study is designed to evaluate the efficacy of a 5g daily dose of TOTUM-070 on blood LDL-cholesterol levels, its primary endpoint. The study will include 120 people with LDL-cholesterol levels between 130 and 190 mg/dL. Results are expected in early 2022.
Development of TOTUM-070 stepped up in 2021
Simultaneously with the HEART study, VALBIOTIS has decided to conduct a complementary clinical study to expand knowledge of TOTUM-070 and its effects on lipid metabolism in humans. Conducted on a limited number of volunteers, it will combine a bioavailability study, metabolomic analysis (characterization and quantification of TOTUM-070 metabolites) and targeted ex-vivo mode of action tests on human cell models, mainly hepatic. Results are expected before the end of 2021.
Finally, a series of preclinical experiments will be launched and completed in 2021. Conducted on the VALBIOTIS R&D platform, this work is intended to detail the impact of TOTUM-070 on lipid metabolism in a predictive model of human pathophysiology. The results will be submitted to the annual meeting of the American Heart Association (AHA), the leading American learned society in the cardiovascular field, to be held from November 13 to 15, 2021.
Once development is complete, TOTUM-070, a new Health Nutrition product, will be positioned for individuals with LDL-hypercholesterolemia, at levels up to 190 mg/dL, with a moderate overall cardiovascular risk. At the end of 2020, the Company provided detailed market data on hypercholesterolemia and the role of TOTUM-070 in its management (see press release of October 27, 2020 ).
ABOUT THE HEART STUDY
The Phase II HEART clinical study is designed to evaluate the efficacy of a 5g daily dose of TOTUM-070 on blood LDL-cholesterol levels, a risk factor for cardiovascular disease, in the absence of lipid-lowering treatment.
This randomized, double-blind, placebo-controlled, multicenter study will include 120 people with untreated moderate hypercholesterolemia and blood LDL-cholesterol levels between 130 and 190 mg/dL. Participants will be divided into 2 equivalent arms of 60 people, supplemented for 6 months with TOTUM-070 or placebo.
The primary endpoint of the study will be the reduction of blood LDL-cholesterol levels, with several metabolic secondary endpoints of interest.
ABOUT TOTUM-070
TOTUM-070 is an innovative active substance derived from food plant extracts, without phytosterols or red rice yeast, developed to act on lipid metabolism in hypercholesterolemic individuals.
Once development is complete, this new Health Nutrition product will be positioned in particular for people with LDL-hypercholesterolemia, at levels up to 190 mg/dL, with a moderate overall cardiovascular risk. TOTUM-070 may be recommended in this large population for whom no first-line drug treatment is currently recommended, with the aim of reducing LDL-cholesterol levels and thus overall cardiovascular risk.
ABOUT VALBIOTIS
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
For more information about VALBIOTIS, please visit: www.valbiotis.com
.
Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150
DISCLAIMER
This press release contains forward-looking statements about VALBIOTIS' objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com
).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005407/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release
- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release
New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release
From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge
RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release
A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo
Global Beauty Market Grows 10% as AI and E-commerce Reshape Consumer Buying1.4.2026 03:00:00 CEST | Press release
Online sales outpace in-store by 6x as digital-first and AI-influenced commerce accelerates globally NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its State of Beauty 2026 report, showing the global beauty market grew 10% year-on-year, with E-commerce expanding six times faster than in-store sales. The findings highlight a rapid shift to digital-first, AI-influenced commerce across key global markets. As consumer expectations evolve toward convenience, personalization, and seamless digital experiences, beauty brands are under increasing pressure to adapt. From AI-powered product discovery to social commerce and livestream shopping, the path to purchase is becoming more dynamic—requiring brands to move faster and engage consumers across an increasingly complex ecosystem. Key findings from the State of Beauty 2026 report: Global beauty sales grew 10% year-over-year, driven by strong digital acceleration E-commerce is growing 6x faster than in-store sales,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom